Adverse effects of glucocorticoids: Coagulopathy

European Journal of Endocrinology

Volumn 173, Issue 4, 2015, Pages M11-M21

  Coelho, Maria Caroline Alves ^a,b,c   Santos, Camila Vicente ^a,c   Neto, Leonardo Vieira ^a,d   Gadelha, Mônica R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^c Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^d HOSPITAL FEDERAL DA LAGOA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; GLUCOCORTICOID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CUSHING SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; BLOOD COAGULATION DISORDERS; COMPLICATION; METABOLISM; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; CUSHING SYNDROME; FACTOR IX; FACTOR VIII; GLUCOCORTICOIDS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; VON WILLEBRAND FACTOR;

EID: 84942789536     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0198     Document Type: Conference Paper

References (54)

1. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2003 88 5593-5602. (doi:10.1210/jc.2003-030871.
2. Fallo F & Sonino N. Should we evaluate for cardiovascular disease in patients with Cushing's syndrome? Clinical Endocrinology 2009 71 768-771. (doi:10.1111/j.1365-2265.2009.03610.x.
3. Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM & Sorensen HT. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. Journal of Clinical Endocrinology and Metabolism 2013 98 2277-2284. (doi:10.1210/jc.2012-3582.
4. Clayton RN, Raskauskiene D, Reulen RC & Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism 2011 96 632-642. (doi:10.1210/jc.2010-1942.
5. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S & Girolami A. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagulation & Fibrinolysis 1999 10 145-151. (doi:10.1097/00001721-199904000-00006.
6. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M & Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagulation & Fibrinolysis 1992 3 789-793. (doi:10.1097/00001721-199212000-00013.
7. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S & Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thrombosis and Haemostasis 1985 54 518-520.
8. Obuobie K, Davies JS, Ogunko A & Scanlon MF. Venous thromboembolism following inferior petrosal sinus sampling in Cushing's disease. Journal of Endocrinological Investigation 2000 23 542-544. (doi:10.1007/BF03343772.
9. Semple PL & Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. Journal of Neurosurgery 1999 91 175-179. (doi:10.3171/jns.1999.91.2.0175.
10. La-Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P & Angeli A. Recurrent thromboembolism as a hallmark of Cushing's syndrome. Journal of Endocrinological Investigation 1997 20 211-214. (doi:10.1007/BF03346905.
11. Skrha J. Pathogenesis of angiopathy in diabetes. Acta Diabetologica 2003 40 (Suppl 2) S324-S329. (doi:10.1007/s00592-003-0113-z.
12. Etxabe J & Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology 1994 40 479-484. (doi:10.1111/j.1365-2265.1994.tb02486.x.
13. Mancini T, Kola B, Mantero F, Boscaro M & Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768-777. (doi:10.1111/j.1365-2265.2004.02168.x.
14. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I & Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009 36 70-74. (doi:10.1007/s12020-009-9186-y.
15. Small M, Lowe GD, Forbes CD & Thomson JA. Thromboembolic complications in Cushing's syndrome. Clinical Endocrinology 1983 19 503-511. (doi:10.1111/j.1365-2265.1983.tb00025.x.
16. Savage B, Shattil SJ & Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin a IIb b 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. Journal of Biological Chemistry 1992 267 11300-11306.
17. Morrison SA & Jesty J. Tissue factor-dependent activation of tritiumlabeled factor IX and factor X in human plasma. Blood 1984 63 1338-1347.
18. Gailani D, Broze GJ Jr & Factor XI. activation in a revised model of blood coagulation. Science 1991 253 909-912. doi:10.1126/science.1652157.
19. Von-dem-Borne PA, Meijers JC & Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995 86 3035-3042.
20. Collen D. The plasminogen (fibrinolytic) system. Thrombosis and Haemostasis 1999 82 259-270.
21. Miljic P, Miljic D, Cain JW, Korbonits M & Popovic V. Pathogenesis of vascular complications in Cushing's syndrome. Hormones 2012 11 21-30.
22. BartonM, Baretella O &Meyer MR. Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. British Journal of Pharmacology 2012 165 591-602. (doi:10.1111/j.1476-5381.2011.01472.x.
23. Eriksson L & Nystrom T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovascular Diabetology 2014 13 152. (doi:10.1186/s12933-014-0152-5.
24. Kang KT. Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicological Research 2014 30 141-148. (doi:10.5487/TR.2014.30.3.141.
25. Kim JA, Montagnani M, Chandrasekran S & Quon MJ. Role of lipotoxicity in endothelial dysfunction. Heart Failure Clinics 2012 8 589-607. (doi:10.1016/j.hfc.2012.06.012.
26. Muniyappa R & Sowers JR. Role of insulin resistance in endothelial dysfunction. Reviews in Endocrine & Metabolic Disorders 2013 14 5-12. (doi:10.1007/s11154-012-9229-1.
27. Prazny M, Jezkova J, Horova E, Lazarova V, Hana V, Kvasnicka J, Pecen L, Marek J, Skrha J & Krsek M. Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: influence of arterial hypertension. Physiological Research 2008 57 13-22.
28. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A & Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome - A hypothesis. Journal of Clinical Endocrinology and Metabolism 2009 94 2692-2701. (doi:10.1210/jc.2009-0370.
29. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Durmus I, Korkmaz L & Celik S. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome. Endocrine 2007 31 300-304. (doi:10.1007/s12020-007-0033-8.
30. Ikkala E, Myllyla G, Pelkonen R, Rasi V, Viinikka L & Ylikorkala O. Haemostatic parameters in Cushing's syndrome. Acta Medica Scandinavica 1985 217 507-511. (doi:10.1111/j.0954-6820.1985.tb03254.x.
31. Daidone V, Boscaro M, Pontara E, Cattini MG, Occhi G, Scaroni C, Mantero F & Casonato A. New insight into the hypercoagulability of Cushing's syndrome. Neuroendocrinology 2011 93 121-125. (doi:10.1159/000323765.
32. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM & Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3662-3666. (doi:10.1210/jc.87.8.3662.
33. Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A & Camaschella C. Hyperhomocysteinemia in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 3745-3751. (doi:10.1210/jc.2004-0079.
34. Kastelan D, Dusek T, Kraljevic I & Aganovic I. Hypercoagulable state in Cushing's syndrome is reversible following remission. Clinical Endocrinology 2013 78 102-106. (doi:10.1111/j.1365-2265.2012.04479.x.
35. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O & Onder Ersoz H. Blood coagulation and fibrinolysis in patients with Cushing'ssyndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. Journal of Endocrinological Investigation 2009 32 169-174. (doi:10.1007/BF03345709.
36. Van-der-Pas R, de-Bruin C, Leebeek FW, de-Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. Journal of Clinical Endocrinology and Metabolism 2012 97 1303-1310. (doi:10.1210/jc.2011-2753.
37. Coelho MC, Vieira Neto L, Kasuki L, Wildemberg LE, Santos CV, Castro G, Gouvea G, Veloso OC, Gadelha T & Gadelha MR. Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome. Clinical Endocrinology 2014 81 657-664. (doi:10.1111/cen.12491.
38. Barbot M, Daidone V, ZilioM, Albiger N, Mazzai L, Sartori MT, Frigo AC, Scanarini M, Denaro L, Boscaro M et al. Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing? Pituitary 2015 In press. (doi:10.1007/s11102-014-0600-y.
39. Dal-Bo-Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F & Girolami A. Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thrombosis and Haemostasis 1982 47 116-117.
40. Koutroumpi S, Daidone V, Sartori MT, Cattini MG, Albiger NM, Occhi G, Ferasin S, Frigo A, Mantero F, Casonato A et al. Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary 2013 16 175-181. (doi:10.1007/s11102-012-0398-4.
41. O'Donnell J & Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfusion Medicine 2001 11 343-351. (doi:10.1046/j.1365-3148.2001.00315.x.
42. Van-Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Buller HR & Brandjes DP. Hypercoagulable state in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 2009 94 2743-2750. doi:10.1210/jc.2009-0290.
43. Patrassi GM, Martinelli S, Sturniolo GC, Cappellato MG, Vicariotto M & Girolami A. Fibrinolytic study in plasma and ascitic fluid of cirrhotic patients before and after ascites concentration; reinfusion technique. European Journal of Clinical Investigation 1985 15 161-165. (doi:10.1111/j.1365-2362.1985.tb00162.x.
44. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F & Mannucci PM. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. Journal of Endocrinological Investigation 2000 23 145-150. (doi:10.1007/BF03343697.
45. Koster T, Rosendaal FR, Reitsma PH, van-der-Velden PA, Briet E & Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thrombosis and Haemostasis 1994 71 719-722.
46. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Reviews 2009 23 225-229. (doi:10.1016/j.blre.2009.07.002.
47. Fahlbusch R, Buchfelder M & Muller OA. Transsphenoidal surgery for Cushing's disease. Journal of the Royal Society of Medicine 1986 79 262-269.
48. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J & Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clinical Endocrinology 2002 56 541-551. (doi:10.1046/j.1365-2265.2002.01511.x.
49. Sudhakar N, Ray A & Vafidis JA. Complications after trans-sphenoidal surgery: our experience and a review of the literature. British Journal of Neurosurgery 2004 18 507-512. (doi:10.1080/02688690400012459.
50. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A & Martino E. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. European Journal of Endocrinology 2010 163 783-791. (doi:10.1530/EJE-10-0583.
51. Stuijver DJ, van-Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, van-den-Berg G, Pereira AM, de-Herder WW, Wagenmakers MA et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. Journal of Clinical Endocrinology and Metabolism 2011 96 3525-3532. (doi:10.1210/jc.2011-1661.
52. Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L & Sorensen HT. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Internal Medicine 2013 173 743-752. (doi:10.1001/jamainternmed.2013.122.
53. Garcia Rodriguez LA & Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. British Journal of Clinical Pharmacology 1998 45 419-425. (doi:10.1046/j.1365-2125.1998.00701.x.
54. Prandoni P. Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: clinical implications of the recent European guidelines. Thrombosis Journal 2008 6 13. (doi:10.1186/1477-9560-6-13.